Network Benchmarks

Anonymized, audit-grade biotech investment benchmarks — published quarterly starting Q4 2026.

Median trial costs by indication × modality. Phase-by-phase duration distributions. Sponsor pattern signals. All anonymized, all citable, all free at the headline level.

What's Coming Q4 2026

• · Median Phase II trial cost by indication (top 12 indications)
• · Phase-to-approval timeline distributions
• · PoS multiplier effective values (network-calibrated)
• · Annual data dump in CSV + JSON, suitable for academic citation